EDITORIAL

PHYTOMEDICINE IN FOCUS: UNLOCKING THE POTENTIAL OF MEDICINAL PLANTS FOR CANCER THERAPY

Punam Desai

Department of Pharmaceutical Sciences and Drug Research,
College of Pharmacy,
Pune, Maharashtra, India.

Correspondence:
Dr. Punam Desai,
Department of Pharmaceutical Sciences and Drug Research,
College of Pharmacy,
Pune, Maharashtra, India.
E-id:punam.desai2211@gmail.com

How to cite this article: Patel S. Phytomedicine in focus: unlocking the potential of medicinal plants for cancer therapy Innov Pharm Planet (IP-Planet) 2021;09(3) 41-43.

Source of Support: Nil.

Conflicts of Interest: None declared.

Date of Submission: 20-07-2021
Date of Revision: 05-08-2021
Date of Acceptance: 22-08-2021

INTRODUCTION

Cancer continues to be one of the leading causes of morbidity and mortality worldwide, with its global burden expected to rise significantly in the coming decades. Despite remarkable advancements in conventional cancer treatments, including chemotherapy, radiotherapy, and immunotherapy, challenges such as drug resistance, severe side effects, and high treatment costs persist. These limitations highlight the urgent need for novel, effective, and affordable therapeutic strategies to complement existing treatments and improve patient outcomes.[1]

Phytomedicine, the use of plant-derived compounds for therapeutic purposes, has emerged as a promising alternative and complementary approach in cancer therapy. Historically rooted in traditional medicine systems, phytomedicine has gained scientific validation due to the discovery of potent anticancer agents derived from plants, such as paclitaxel from Taxus brevifolia and vincristine from Catharanthus roseus. These discoveries underscore the potential of phytochemicals to provide innovative solutions in cancer treatment by targeting diverse pathways involved in tumor progression and metastasis.[2]

In 2021, the relevance of phytomedicine to the pharmaceutical field is underscored by growing interest in sustainable and integrative health practices. Advances in extraction technologies, pharmacological studies, and clinical research are enabling the translation of traditional plant-based knowledge into modern, evidence-based oncology therapeutics. As the pharmaceutical industry seeks to innovate while addressing global health challenges, phytomedicine represents a critical frontier in the fight against cancer, offering hope for more effective and accessible treatments.

Historical Perspective on Medicinal Plants in Cancer Therapy

The use of medicinal plants for therapeutic purposes dates back thousands of years and spans across cultures and civilizations. Ancient medical systems such as Ayurveda, Traditional Chinese Medicine (TCM), and Greco-Arab medicine have extensively utilized plant-based remedies for treating a wide array of ailments, including conditions resembling cancer. Plants such as *Curcuma longa* (turmeric), *Camellia sinensis* (green tea), and *Podophyllum peltatum* (mayapple) have been valued for their healing properties and are still central to traditional practices in many parts of the world.[3]

Modern medicine has built upon this traditional knowledge to identify and isolate bioactive compounds with potent anticancer properties. A key milestone in this journey was the discovery of vinca alkaloids, vincristine and vinblastine, derived from *Catharanthus roseus* (Madagascar periwinkle). These compounds revolutionized cancer therapy in the mid-20th century with their efficacy in treating leukemias and lymphomas.[4] Similarly, the discovery of paclitaxel (Taxol®) from the bark of the Pacific yew tree (Taxus brevifolia) marked a breakthrough in the treatment of ovarian and breast cancers, providing a foundation for plant-based chemotherapy agents.[5]

These milestones highlight the immense potential of phytomedicine as a rich reservoir of bioactive compounds. They also emphasize the importance of integrating traditional knowledge with modern scientific methodologies to uncover and harness the therapeutic potential of medicinal plants. The historical trajectory of medicinal plants in cancer therapy underscores their enduring relevance and serves as a reminder of the untapped opportunities within the plant kingdom for addressing today's pressing health challenges.

Recent Advances in Phytomedicine Research

Recent years have witnessed significant progress in the field of phytomedicine, driven by advancements in phytochemical isolation, screening techniques, and

Access this article online

Website: https://innovationaljournals.com/index.php/ip | **e-ISSN:** 2348-7275

analytical technologies. High-performance liquid chromatography (HPLC), mass spectrometry (MS), nuclear magnetic resonance (NMR), and bioassay-guided fractionation have become pivotal tools in isolating and identifying bioactive compounds from medicinal plants. These techniques have enabled researchers to pinpoint phytochemicals with potent anticancer properties and to understand their mechanisms of action at molecular and cellular levels.[6]

Among the most promising plant-derived compounds for cancer treatment are curcumin, berberine, and resveratrol, which have garnered considerable attention for their diverse pharmacological activities.

Curcumin from Curcuma longa

Curcumin, the active compound in turmeric, exhibits remarkable anticancer properties, including the ability to induce apoptosis, inhibit angiogenesis, and modulate multiple signaling pathways involved in cancer progression. Its effectiveness has been demonstrated in preclinical models for a variety of cancers, such as breast, colon, and pancreatic cancers. Efforts to improve curcumin's bioavailability through novel formulations, such as nanoparticles and liposomes, have further enhanced its therapeutic potential.[7]

Berberine from Berberis aristata

Berberine, an isoquinoline alkaloid, is recognized for its broad spectrum of anticancer activities. It disrupts cancer cell proliferation, induces cell cycle arrest, and exhibits anti-inflammatory and antioxidant effects. Berberine has shown promise in treating cancers such as lung, prostate, and liver cancer, making it a strong candidate for integrative cancer therapy.[8]

Resveratrol from Grapes

Resveratrol, a polyphenolic compound found in grapes and red wine, has been extensively studied for its anticancer properties. It exerts its effects through multiple pathways, including the inhibition of tumor cell proliferation, induction of apoptosis, and suppression of metastasis. Additionally, resveratrol enhances the efficacy of conventional chemotherapeutic agents, making it a valuable adjunct in cancer treatment.[9]

These compounds exemplify the potential of phytomedicine to offer safer and more effective therapeutic options for cancer management. Ongoing research continues to explore new plant-derived molecules, aiming to expand the arsenal of anticancer agents and integrate them into modern oncological practice.

Mechanisms of Action

Phytochemicals exert their anticancer effects through a variety of mechanisms that target the hallmarks of cancer. One key mechanism is the induction of apoptosis, a programmed cell death pathway that eliminates cancer cells without harming normal tissues.[10] Compounds like curcumin and berberine activate caspases and disrupt mitochondrial integrity to initiate this process. Another significant mechanism is the inhibition of angiogenesis and metastasis, where phytochemicals, such as resveratrol, prevent tumor vascularization and block the spread of cancer cells to distant sites.[11] Additionally, many plant-derived compounds modulate the immune system, enhancing the body's ability to recognize and destroy cancer cells. These multifaceted actions make phytochemicals a compelling area of research for integrative cancer therapies.

Challenges and Limitations

Despite their potential, plant-based compounds face challenges in clinical application. Bioavailability and pharmacokinetics are major issues; many phytochemicals have poor absorption, rapid metabolism, and low systemic concentrations, limiting their therapeutic efficacy. Variability in phytochemical content due to environmental factors, soil conditions, and plant sources further complicates standardization. Moreover, the lack of large-scale, rigorously designed clinical trials hampers the establishment of clear efficacy and safety profiles, impeding their acceptance in mainstream oncology. Addressing these challenges is crucial for advancing phytomedicine in cancer therapy.[12]

Phytomedicine in Modern Drug Development

The integration of phytomedicine with modern technologies offers exciting possibilities. Nanotechnology, for instance, enables targeted drug delivery systems that enhance the bioavailability and therapeutic index of phytochemicals. Furthermore, combining phytochemicals with conventional chemotherapy has shown synergistic effects, improved treatment efficacy while reducing side effects. The advent of personalized medicine, guided by genomic studies, also opens opportunities for tailoring phytochemical-based therapies to individual patient profiles, maximizing their effectiveness.[13]

Future directions

The future of phytomedicine in oncology lies in fostering interdisciplinary research collaborations among pharmacologists, botanists, and oncologists. Such partnerships can accelerate the discovery and validation of novel anticancer agents. Exploring unexamined plant species, particularly from biodiverse regions, may yield new bioactive compounds with untapped therapeutic potential. Additionally, the sustainable harvesting and conservation of medicinal plants are vital to preserving this resource for future generations and ensuring ecological balance.

Conclusion

Phytomedicine offers promising, less toxic alternatives for cancer therapy, with potential to transform oncology. Continued research, innovation, and robust regulatory frameworks are vital to fully realize its benefits. Integrating plant-based pharmaceuticals supports sustainable, patient-centered healthcare, emphasizing its relevance for advancements in 2021 and beyond.

References

1. Torre, L. A., Siegel, R. L., Ward, E. M., & Jemal, A. (2016). Global cancer incidence and mortality rates and trends—an update. Cancer epidemiology, biomarkers & prevention, 25(1), 16-27.
2. Kumar, V. V., Swamy, M. K., & Akhtar, M. S. (2018). Anticancer plants and their conservation strategies: an update. Anticancer plants: Properties and Application: Volume 1, 455-483.
3. Pan, S. Y., Litscher, G., Gao, S. H., Zhou, S. F., Yu, Z. L., Chen, H. Q., ... & Ko, K. M. (2014). Historical perspective of traditional indigenous medical practices: the current renaissance and conservation of herbal resources. Evidence-Based Complementary and Alternative Medicine, 2014(1), 525340.
4. Garden, M. P. (2010). Guide to the Medicinal Plant Garden. Indiana Medical History Museum, 46222(317), 22.
5. Lee, W. L., Shiau, J. Y., & Shyur, L. F. (2012). Taxol, camptothecin and beyond for cancer therapy. In Advances in Botanical Research (Vol. 62, pp. 133-178). Academic Press.
6. Brusotti, G., Cesari, I., Dentamaro, A., Caccialanza, G., & Massolini, G. (2014). Isolation and characterization of bioactive compounds from plant resources: the role of analysis in the ethnopharmacological approach. Journal of pharmaceutical and biomedical analysis, 87, 218-228.
7. Aggarwal, B. B., Yuan, W., Li, S., & Gupta, S. C. (2013). Curcumin-free turmeric exhibits anti-inflammatory and anticancer activities: Identification of novel components of turmeric. Molecular nutrition & food research, 57(9), 1529-1542.
8. Pai, K. S. R., Srilatha, P., Suryakant, K., Setty, M. M., Nayak, P. G., Rao, C. M., & Baliga, M. S. (2012). Anticancer activity of Berberis aristata in Ehrlich ascites carcinoma-bearing mice: a preliminary study. Pharmaceutical biology, 50(3), 270-277.
9. Ko, J. H., Sethi, G., Um, J. Y., Shanmugam, M. K., Arfuso, F., Kumar, A. P., ... & Ahn, K. S. (2017). The role of resveratrol in cancer therapy. International journal of molecular sciences, 18(12), 2589.
10. Ouyang, L., Shi, Z., Zhao, S., Wang, F. T., Zhou, T. T., Liu, B., & Bao, J. K. (2012). Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell proliferation, 45(6), 487-498.
11. Wang, Z., Dabrosin, C., Yin, X., Fuster, M. M., Arreola, A., Rathmell, W. K., ... & Jensen, L. D. (2015, December). Broad targeting of angiogenesis for cancer prevention and therapy. In Seminars in cancer biology (Vol. 35, pp. S224-S243). Academic Press.
12. Rathaur, P., & SR, K. J. (2019). Metabolism and pharmacokinetics of phytochemicals in the human body. Current drug metabolism, 20(14), 1085-1102.
13. Kurhekar, J. V. (2021). Ancient and modern practices in phytomedicine. In Preparation of Phytopharmaceuticals for the Management of Disorders (pp. 55-75). Academic Press.